B D Smith

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
    Mark Levis
    Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD 21231 1000, USA
    Blood 99:3885-91. 2002
  2. ncbi request reprint Acute myeloid leukemia clinical practice guidelines in oncology
    Margaret R O'Donnell
    City of Hope Cancer Center, Los Angeles, CA, USA
    J Natl Compr Canc Netw 4:16-36. 2006
  3. ncbi request reprint Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
    B Douglas Smith
    Departments of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Blood 103:3669-76. 2004
  4. ncbi request reprint Curing acute myelogenous leukemia: still a major challenge
    B Douglas Smith
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Leuk Res 29:607-8. 2005
  5. ncbi request reprint Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experience
    B Douglas Smith
    Johns Hopkins Oncology Center, Bunting Blaustein Cancer Research Building, Rm 246, 1650 Orleans Street, Baltimore, MD 21231, USA
    Br J Haematol 117:907-13. 2002
  6. ncbi request reprint The role of growth factors in the activity of pharmacological differentiation agents
    William H Matsui
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Cell Growth Differ 13:275-83. 2002
  7. ncbi request reprint A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations
    M Levis
    Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD 21231, USA
    Blood 98:885-7. 2001
  8. ncbi request reprint Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias
    Judith E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Clin Cancer Res 11:8403-12. 2005
  9. ncbi request reprint Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia
    R A Brodsky
    Johns Hopkins Oncology Center, Bunting Blaustein Cancer Research Building, Room 242, 1650 Orleans Street, Baltimore MD 21231, USA
    Ann Intern Med 135:477-83. 2001
  10. ncbi request reprint Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia
    Steven D Gore
    The Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Am J Hematol 79:119-27. 2005

Research Grants

Detail Information

Publications61

  1. ncbi request reprint A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
    Mark Levis
    Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD 21231 1000, USA
    Blood 99:3885-91. 2002
    ..These findings form the basis for a planned clinical trial of CEP-701 in patients with AML harboring FLT3- activating mutations...
  2. ncbi request reprint Acute myeloid leukemia clinical practice guidelines in oncology
    Margaret R O'Donnell
    City of Hope Cancer Center, Los Angeles, CA, USA
    J Natl Compr Canc Netw 4:16-36. 2006
  3. ncbi request reprint Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
    B Douglas Smith
    Departments of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Blood 103:3669-76. 2004
    ..Our results show that FLT3 inhibition is associated with clinical activity in AML patients harboring FLT3-activating mutations and indicate that CEP-701 holds promise as a novel, molecularly targeted therapy for this disease...
  4. ncbi request reprint Curing acute myelogenous leukemia: still a major challenge
    B Douglas Smith
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Leuk Res 29:607-8. 2005
  5. ncbi request reprint Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experience
    B Douglas Smith
    Johns Hopkins Oncology Center, Bunting Blaustein Cancer Research Building, Rm 246, 1650 Orleans Street, Baltimore, MD 21231, USA
    Br J Haematol 117:907-13. 2002
    ..4HC-purged autologous BMT produced results similar to allogeneic BMT for AML patients beyond first remission...
  6. ncbi request reprint The role of growth factors in the activity of pharmacological differentiation agents
    William H Matsui
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Cell Growth Differ 13:275-83. 2002
    ..These data suggest that many pharmacological differentiating agents require both cell cycle arrest and lineage-specific growth factors for full activity and may explain why these agents have demonstrated only limited clinical efficacy...
  7. ncbi request reprint A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations
    M Levis
    Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD 21231, USA
    Blood 98:885-7. 2001
    ..The results suggest that these mutations contribute to the leukemic process and that the FLT3 receptor represents a therapeutic target in AML. (Blood. 2001;98:885-887)..
  8. ncbi request reprint Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias
    Judith E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Clin Cancer Res 11:8403-12. 2005
    ....
  9. ncbi request reprint Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia
    R A Brodsky
    Johns Hopkins Oncology Center, Bunting Blaustein Cancer Research Building, Room 242, 1650 Orleans Street, Baltimore MD 21231, USA
    Ann Intern Med 135:477-83. 2001
    ..A small pilot study demonstrated that high-dose cyclophosphamide therapy without bone marrow transplantation leads to durable, treatment-free complete remission...
  10. ncbi request reprint Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia
    Steven D Gore
    The Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Am J Hematol 79:119-27. 2005
    ..However, the toxicity of the consolidation module and the development of secondary myelodysplasia despite decreased total therapy emphasize the need to further improve and refine curative therapy for APL...
  11. ncbi request reprint High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement
    Yvette L Kasamon
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 11:93-100. 2005
    ..These data suggest that patients with lymphomatous involvement of the CNS who achieve CNS remission should be offered BMT if it is otherwise indicated...
  12. pmc Induction of acute lymphocytic leukemia differentiation by maintenance therapy
    T L Lin
    The Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Leukemia 21:1915-20. 2007
    ..These data suggest that induction of leukemia progenitor differentiation plays an important role in the mechanism of action of maintenance therapy in ALL...
  13. pmc Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen
    J Bolanos-Meade
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Bone Marrow Transplant 43:477-80. 2009
    ..The combination of fludarabine and alemtuzumab is an effective and well-tolerated salvage conditioning regimen for patients who experience graft failure after blood or marrow transplants...
  14. pmc What are the endpoints of therapy for acute leukemias? Old definitions and new challenges
    B Douglas Smith
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Clin Lymphoma Myeloma 9:S296-301. 2009
    ....
  15. ncbi request reprint Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant
    Greg R Angstreich
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room 207, Baltimore, MD 21231, USA
    Curr Opin Oncol 16:95-9. 2004
    ..Additionally, the review discusses advances in the basic understanding of the mechanisms by which these three different therapies function against chronic myeloid leukemia...
  16. ncbi request reprint Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes
    W H Matsui
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Leukemia 20:458-62. 2006
    ..Quantification of marrow CD34+ cells may serve as an important tool for distinguishing between AA and hMDS...
  17. ncbi request reprint Myelodysplastic syndromes: review of pathophysiology and current novel treatment approaches
    E D Warlick
    Hematologic Malignancies Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, room 246 Baltimore, MD 21231, USA
    Curr Cancer Drug Targets 7:541-58. 2007
    ....
  18. pmc A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias
    Judith E Karp
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Blood 110:1762-9. 2007
    ..This clinical trial is registered with the National Cancer Institute's PDQ at www.clinicaltrials.gov as no. JHOC-J0561...
  19. pmc Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors
    Mark Levis
    Kimmel Cancer Center at Johns Hopkins University, Baltimore, MD 21231, USA
    Blood 108:3477-83. 2006
    ..Additionally, our results suggest that nonselectivity may constitute an important component of the cytotoxic effect of FLT3 inhibitors in FLT3-mutant AML...
  20. ncbi request reprint Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 12:414-21. 2006
    ..However, with the exception of CML, most patients die of their underlying disease because of insufficient antitumor activity even with active GVHD...
  21. ncbi request reprint Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia
    Judith E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 13:4467-73. 2007
    ..We have now completed a phase II study of sequential flavopiridol, ara-C, and mitoxantrone in 62 adults with poor-risk AML...
  22. pmc Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance
    William Matsui
    The Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Res 68:190-7. 2008
    ..Our results suggest that circulating clonotypic B-cell populations represent multiple myeloma stem cells, and the relative drug resistance of these cells is mediated by processes that protect normal stem cells from toxic injury...
  23. pmc Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features
    Judith E Karp
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, USA
    Clin Cancer Res 14:3077-82. 2008
    ..Tipifarnib is an oral farnesyltransferase inhibitor with activity in AML. We conducted a phase II trial of maintenance tipifarnib monotherapy for 48 adults with poor-risk AML in first CR...
  24. pmc Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide
    Judith E Karp
    Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD 21231 1000, USA
    Blood 113:4841-52. 2009
    ..These clinical studies are registered at www.clinicaltrials.gov as #NCT00112853...
  25. pmc Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
    Judith E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Leuk Res 34:877-82. 2010
    ..Short OS and DFS correlated with adverse cytogenetics, regardless of age or treatment in CR. The addition of allogeneic BMT in CR translates into long OS and DFS in the majority of eligible patients...
  26. pmc High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up
    Robert A Brodsky
    Division of Hematology, Department of Medicine, Johns Hopkins University School ofMedicine, 720 Rutland Ave, Ross Bldg, Rm 1025, Baltimore, MD 21205, USA
    Blood 115:2136-41. 2010
    ....
  27. pmc K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate
    B Douglas Smith
    Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and St Agnes Hospital, Baltimore, Maryland 21231, USA
    Clin Cancer Res 16:338-47. 2010
    ..A pilot study was developed to determine if K562/GM-CSF immunotherapy could improve clinical responses to imatinib mesylate (IM) in patients with chronic myeloid leukemia...
  28. pmc High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Blood 115:3224-30. 2010
    ..These results suggest that high-dose posttransplantation cyclophosphamide is an effective single-agent prophylaxis of acute and chronic GVHD after BuCy conditioning and HLA-matched BMT (clinicaltrials.gov no. NCT00134017)...
  29. pmc Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib
    Brady Stein
    Division of Hematology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Clin Ther 32:804-20. 2010
    ..However, its use is complicated by development of resistance or drug intolerance, prompting dose escalation or a trial of dasatinib or nilotinib, the second-generation tyrosine kinase inhibitors (TKIs)...
  30. ncbi request reprint Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms
    Steven D Gore
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21287, USA
    Cancer Res 66:6361-9. 2006
    ..The promising percentage of major hematologic responses justifies the testing of such combinations in prospective randomized trials...
  31. ncbi request reprint Cancer stem cells: are we missing the target?
    Richard J Jones
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Natl Cancer Inst 96:583-5. 2004
  32. pmc Internal tandem duplications of the FLT3 gene are present in leukemia stem cells
    Mark Levis
    Blood 106:673-80. 2005
    ..Taken together, these experiments establish that the FLT3/ITD mutations are present in leukemia stem cells, and that FLT3 inhibitors may have activity against these cells...
  33. ncbi request reprint Trying to improve clinical outcome in AML: lessons from negative trials
    Judith E Karp
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room 289, Baltimore, Maryland 21231 1000, USA
    Leuk Res 29:603-4. 2005
  34. ncbi request reprint In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects
    Mark Levis
    Department of Oncology, Baltimore, MD 21231, USA
    Blood 104:1145-50. 2004
    ..These results should be considered when designing trials combining chemotherapy with each of the FLT3 inhibitors currently in clinical development...
  35. pmc Characterization of clonogenic multiple myeloma cells
    William Matsui
    Sidney Kimmel Comprehensive Cancer Center, John Hopkins University School of Medicine, Bunting Blaustein Cancer Research Bldg, Rm 245, 1650 Orleans St, Baltimore, MD 21231, USA
    Blood 103:2332-6. 2004
    ..These data suggest that MM "stem cells" are CD138- B cells with the ability to replicate and subsequently differentiate into malignant CD138+ plasma cells...
  36. pmc Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay
    Kathleen M Murphy
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21287, USA
    J Mol Diagn 5:96-102. 2003
    ..Here we describe the performance characteristics of the assay, assay validation, and our clinical experience using this assay to analyze 147 clinical specimens...
  37. ncbi request reprint Anti-tumour activity of interferon-alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiation
    William Matsui
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Br J Haematol 121:251-8. 2003
    ..These results suggest that the differentiating activities of IFN-alpha may play a role in its clinical antimyeloma activity and provide the rationale for clinical differentiation therapy in MM...
  38. pmc The paradox of response and survival in cancer therapeutics
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Blood 107:431-4. 2006
    ..In this article, we discuss the evidence for cancer stem cells in hematologic malignancies and possible ways to begin targeting these cells and measuring clinical effectiveness of such treatment approaches...
  39. ncbi request reprint Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia
    William Matsui
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Br J Haematol 128:853-62. 2005
    ..The combined use of pharmacologic differentiating agents and growth factors may improve the clinical efficacy of differentiation therapy in APL...
  40. pmc Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation
    Elizabeth A Griffiths
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Leuk Lymphoma 51:1711-9. 2010
    ....
  41. pmc A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias
    K W Pratz
    Division of Hematologic Malignancies, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Leukemia 24:1437-44. 2010
    ..Although sorafenib showed only modest clinical activity as a single agent in this heavily treated population, robust inhibition of FLT3 and ERK suggests that there may be a potential important role in combination therapies...
  42. ncbi request reprint Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor
    K F Tse
    Johns Hopkins University School of Medicine, Department of Oncology Baltimore, MD 21231, USA
    Leukemia 16:2027-36. 2002
    ..AG1296 also inhibited FLT3 auto-phosphorylation, and induced a cytotoxic effect, in primary AML cells. These findings suggest that inhibiting the activity of FLT3 may have a therapeutic value in some leukemias expressing FLT3/ITDs...
  43. ncbi request reprint New concepts in the treatment of acute myeloid malignancies: selected pathways for targeted therapy
    B D Smith
    Hematologic Malignancies, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    J Biol Regul Homeost Agents 19:23-32. 2005
    ....
  44. ncbi request reprint New agents in the treatment of acute myeloid leukemia: a snapshot of signal transduction modulation
    Ting Bao
    Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Clin Adv Hematol Oncol 3:287-96, 302. 2005
    ..This review will focus on several exciting components of these pathways and the agents targeting these pathways that are entering clinical trials...
  45. pmc The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivo
    Rebecca C Osthus
    Program in Human Genetics and Molecular Biology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer Res 65:5620-7. 2005
    ..We observed a significant increased incidence of transgenic animal solid tumors, which were not seen in littermate controls. These observations suggest that JPO1/CDCA7 may contribute to Myc-mediated tumorigenesis...
  46. ncbi request reprint Biology and management of idiopathic myelofibrosis
    B D Smith
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Curr Opin Oncol 13:91-4. 2001
    ..The goals of future therapies will target marrow fibrosis and harness the graft-versus-fibrosis effect to safely and effectively treat patients with IMF...
  47. ncbi request reprint Acute bilineal leukemia: a rare disease with poor outcome
    E G Weir
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Leukemia 21:2264-70. 2007
    ..Cytogenetic abnormalities of t(9;22) and 11q23 are common in, and may be restricted to, B-My cases, while T-My cases have frequent but generally non-recurring abnormalities. Both types of aBLL are associated with poor outcome...
  48. pmc Immunotherapy for myeloid leukemias: current status and future directions
    K El-Shami
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Leukemia 22:1658-64. 2008
    ....
  49. ncbi request reprint Ribonucleotide reductase: an old target with new potential
    B Douglas Smith
    Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD 21210, USA
    Leuk Res 27:1075-6. 2003
  50. pmc A rare e14a3 (b3a3) BCR-ABL fusion transcript in chronic myeloid leukemia: diagnostic challenges in clinical laboratory practice
    Natini Jinawath
    Institute of Genetic Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Mol Diagn 11:359-63. 2009
    ....
  51. pmc Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies
    Ying Ye
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Cancer Res 69:8482-90. 2009
    ....
  52. ncbi request reprint Validation and implementation of a method for determination of bryostatin 1 in human plasma by using liquid chromatography/tandem mass spectrometry
    Ming Zhao
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Anal Biochem 337:143-8. 2005
    ..99. The values for both within-day and between-day precision and accuracy were <15%. This method was used to characterize the plasma pharmacokinetics of bryostatin 1 at doses of 20 microg/m2) to optimize treatment with this agent...
  53. ncbi request reprint Developmental clinical trials: building one step at a time
    Judith E Karp
    Leuk Res 30:765-6. 2006
  54. ncbi request reprint Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors
    Greg R Angstreich
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, MD, USA
    Br J Haematol 130:373-81. 2005
    ..At least part of the clinical effect of IFN in CML appears to result from its ability to differentiate primitive CML progenitors...
  55. ncbi request reprint Exploiting oxidative damage to overcome resistance
    Judith E Karp
    Leuk Res 30:1213-4. 2006
  56. ncbi request reprint Response to 'comparison of "sequential" versus "standard" chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R tria
    B Douglas Smith
    Br J Haematol 122:164-5. 2003
  57. ncbi request reprint Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization
    Xue Wei Meng
    Divisions of Oncology Research, Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Biol Chem 282:29831-46. 2007
    ..Collectively, these observations not only suggest a model in which Mcl-1 confers TRAIL resistance by serving as a buffer for Bak, Bim, and Puma, but also identify sorafenib as a potential modulator of TRAIL sensitivity...
  58. ncbi request reprint Chronic myelogenous leukemia
    Susan O'Brien
    J Natl Compr Canc Netw 3:732-55. 2005
  59. ncbi request reprint Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia
    Damiano Rondelli
    Stem Cell Transplant Program, Section Hematology Oncology, University of Illinois at Chicago, 900 S Ashland Ave, Chicago, IL 60607 7171, USA
    Blood 105:4115-9. 2005
    ..The use of RIC regimens in allogeneic stem cell transplantation results in prolonged survival in intermediate/high-risk MMM patients...
  60. pmc Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine
    Ruben A Mesa
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 106:318-27. 2005
    ..Collectively, these results suggest that treatment with 17-AAG might represent a means of reversing checkpoint-mediated cytarabine resistance in AML...

Research Grants1

  1. CYTOKINE MEDIATED DIFFERENTIATION THERAPY
    B Smith; Fiscal Year: 2005
    ..abstract_text> ..